An Unbiased View of lenmeldy
The FDA assessed the protection and performance of atidarsagene autotemcel dependant on data from 37 little ones who received atidarsagene autotemcel in two one-arm, open up-label scientific trials and in an expanded accessibility program.[7] Little ones who received therapy with atidarsagene autotemcel had been compared to untreated kids (organic